Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Food stocks fell at the beginning of the day, and food stocks fell at the beginning, and food stocks fell at the beginning, and Jialong shares, Anji Food, Huang Shanghuang, three squirrels, and Barbie Foods followed suit.Kangxinuo said on the interactive platform that the company is promoting the research and development of a variety of innovative vaccines, submitting applications for related matters in accordance with the guiding principles of CDE, and actively communicating and reporting.
Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Yin Xiyue continued to exercise the presidential power to submit the consent of the appointment of the chief justice to the National Assembly. According to the information system of the Korean National Assembly's motion, South Korean President Yin Xiyue submitted the consent of the appointment of the chief justice to the National Assembly on the 12 th, and said that "with the end of the term of office of the chief justice, in order to appoint a successor judge, the consent of the National Assembly is requested." Yin Xiyue delivered a speech to the people on the 12th, refused to end his term of office ahead of schedule, and successively approved 42 bills and enforcement orders, and also submitted a consent case for the appointment of the chief justice to continue to exercise the presidential power. According to the Korean Constitution, the Chief Justice shall be submitted by the President of the Grand Court of Korea (the High Court) and appointed by the President with the consent of the National Assembly. (CCTV News)Domestic insurance in Hong Kong stocks and Chinese brokerage stocks fluctuated lower, while domestic insurance in Hong Kong stocks and Chinese brokerage stocks fluctuated lower. Guolian Securities fell more than 5%, followed by New China Life Insurance, China Pacific Insurance, China Life Insurance, China Merchants Securities and china galaxy.
The negative spread of 10-year treasury bonds between China and the United States has expanded to more than 250BP, the largest since June 2002.Shenzhen accelerates to build a new generation of world-class automobile cities. The total output of automobiles this year is expected to exceed 2.8 million. Over the past hundred years, many well-known "automobile cities" have emerged continuously in the world automobile industry. As one of the earliest cities to develop new energy industry, Shenzhen has a solid foundation for industrial development, actively seizing the historical opportunity of global automobile industry reform and achieving "overtaking in corners" on new energy automobile tracks. In 2023, the output of new energy vehicles in the city reached 1.733 million, ranking first among cities in China. With the acceleration of intelligent process and the high coordination of industrial chain, a "new generation world-class automobile city" is accelerating in Shenzhen. (Shenzhen Special Zone Daily)Zongheng Communication established a new science and technology company in Zhejiang. The enterprise search APP shows that recently, Zongheng Cross-border Technology (Zhejiang) Co., Ltd. was established with Xu Shasha as its legal representative and a registered capital of 10 million yuan. Its business scope includes: sales of information security equipment; Network equipment sales; Internet of things technical services, etc. Enterprise equity penetration shows that the company is wholly owned by Zongheng Communication.
Strategy guide
Strategy guide
Strategy guide 12-14